Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥ 60 years) with active myeloid malignancies
Open Access
- 15 May 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 105 (10) , 4147-4148
- https://doi.org/10.1182/blood-2005-01-0196
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood, 2004
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSBlood, 2004
- Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 yearsBlood, 2003
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignanciesBlood, 2003
- Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantationBlood, 2003
- Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenBlood, 2002